Background: In many fields of medicine, guidelines recommend reduced cancer screening in patients of advanced age and limited life expectancy (LLE). In dermatology, there are currently no guidelines for adjusted evaluation and management practices of keratinocyte cancer (KC) in patients with LLE. Little is known regarding evaluation and management patterns and frequency of biopsies in these patients. Objective: We sought to determine if dermatology providers biopsy LLE patients with similar frequency to their age-matched peers and quantify frequency of associated complications. Methods: This was a retrospective cohort study of evaluations for skin cancer quantified by skin biopsy frequency for skin cancer at the North Texas Veteran Affairs Health System dermatology clinic for 3062 patients between 2005-2009, including a 5-year follow-up period. Life expectancy was quantified by the validated Charlson Comorbidity Index (CCI) with a Deyo adaptation. Results: There was no significant difference in biopsy frequency of KC in LLE vs non-LLE patients in most age-controlled groups, with increased biopsy frequency in LLE patients in the 65-74 age category (p=0.02). There was also an increased risk of complications from biopsy in the 75-84 (many comorbidities subgroup: RR=3.27, p=0.002; some comorbidities subgroup: RR=2.26, p=0.048) and 65-74 (many comorbidities subgroup: RR=1.52, p=0.004) age group when compared to age matched healthy controls. Conclusion: Biopsy frequency is similar or increased in patients with LLE compared with age-matched controls, with increased frequency of complications. Further studies are needed to understand the underlying factors driving these practice patterns.
L arge congenital masses appropriately raise clinical concern, especially when they do not present with the classic appearance, thus requiring consideration of broad differential diagnostic categories prior to conclusive diagnosis. We discuss analysis and treatment of a vascular lesion most closely resembling a fibrous hamartoma of infancy (FHI). Report of a Case.A 13-day-old healthy female infant presented for evaluation of a "lump" on her right buttock. She was born at 37 weeks' gestation via scheduled cesarean section. Pregnancy was complicated by gestational diabetes, and birth by initial oxygen saturation of 60% that had to be normalized with supplementation. The plaque appeared asymptomatic at birth and had not changed much by the time of presentation. Physical examination revealed a 3 ϫ 2-cm maroon, firm, welldemarcated, nonblanching plaque with a palpable subcutaneous component and overlying hypertrichosis on the right buttock (Figure 1). Manipulation produced piloerection (positive pseudo-Darier sign). Histopathologic analysis revealed two predominant components, a prominent proliferation of spindle-shaped cells admixed with numerous round blood vessels lined by plump endothelial cells throughout the dermis and subcutis (Figure 2).Immunohistochemical staining results were diffusely positive for CD31 and CD34, highlighting capillary structures, and focally positive for CD68, SMA (smooth-muscle antibody), and EMA (epithelial membrane antigen). Findings for S-100 and claudin were negative. The spindle-shaped component was somewhat analogous to that of FHIs but not of involuted hemangiomas. The storiform architecture seen in dermatofibrosarcoma protuberans and endothelial multilayering or atypia to suggest malignancy were lacking. Crescent-shaped vascular spaces, spindled endothelial cells, and hyaline stroma typical of kaposiform hemangioendothelioma were not seen. Over 5 months, the plaque became larger, lighter in color, and less indurated. The patient ultimately underwent surgical excision at age 8 months.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.